SA Pharmaceutical Journal - Volume 83, Issue 3, 2016
Volume 83, Issue 3, 2016
Author Sarel MalanSource: SA Pharmaceutical Journal 83 (2016)More Less
Sitting in a meeting for 4 days, working at giving new prospective pharmaceutical compounds, chemicals as well as biologicals, International Non-proprietary Names (INN), reminded me again of how important a name is. In this case it is about selecting or devising a name that would provide information to the prescriber and the dispenser; a name that would be linked to a mode of action through a common stem; for which there is little chance of confusion with other drug names, no trademark conflicts, and no bad or specifically good connotations in the fantasy prefix that makes up the name in conjunction with the stem.
Source: SA Pharmaceutical Journal 83 (2016)More Less
Young Pharmacists' Group representative for SAAHIP : Eulanda Tshivhidzo The South African Association of Hospital and Institutional Pharmacists (SAAHIP) co-opted a Young Pharmacists' Group (YPG) position on their national executive committee. YPG is proud to introduce Eulanda who will serve in this position and manage the development and involvement of young hospital and institutional pharmacists.
Source: SA Pharmaceutical Journal 83, pp 11 –17 (2016)More Less
Atopic dermatitis (AD), the dermatological manifestation of the atopic diathesis, has a variety of clinical presentations. It is a chronic and relapsing inflammatory disorder, requiring a multifaceted treatment approach. Topical corticosteroids are the backbone of therapy. However, concerns over adverse drug reactions associated with their long-term application limit their use. Tacrolimus, on the other hand, has been shown to be effective in stabilising the symptoms of AD in the long-term setting, without the side-effects that hamper the use of topical corticosteroids. Long-term safety data up to ten years are available in the literature. Despite this, the US Food and Drug Administration (FDA) black box warning of possible malignancies has resulted in much debate among experts. The main focus of this article is to compare the safety and efficacy of topical corticosteroids to calcineurin inhibitors, particularly tacrolimus. Furthermore, the aim is to evaluate the place of tacrolimus in AD therapy. A brief overview of the condition and other treatment modalities will also be discussed.
Source: SA Pharmaceutical Journal 83, pp 18 –21 (2016)More Less
The introduction of antiretroviral therapy transformed the resultant acquired immunodeficiency syndrome (AIDS) from a disease of high morbidity and mortality to a manageable chronic condition, with a subsequent reduction in the negative impact thereof on the world's economy and global healthcare systems. However, patients living with AIDS have now become vulnerable to an increase in morbidity and mortality due to non-AIDS related illness, such as metabolic syndrome, liver and renal failure, and premature cardiovascular disease (CVD); with antiretroviral therapy being especially prone to causing iatrogenic dyslipidaemia, which increases the risk of CVD. This article provides an overview of the nature and management of dyslipidaemia associated with HIV-infection and AIDS.
Author Sumari DavisSource: SA Pharmaceutical Journal 83, pp 22 –26 (2016)More Less
Pharmacists are often approached for advice on common sport injuries, such as sprains and strains. Although some injuries may be managed with rest, ice, compression and elevation, as well as treatment with local or oral anti-inflammatory drugs, others, such as head injuries and fractures, can be serious. They may need referral for further assessment. The extent of the contribution of the inflammatory response to the healing process is currently unknown, but has led some to question the use of ice and anti-inflammatory drugs to suppress this physiological response. Evidence to support this theory is still insufficient and needs further exploration. Short-term treatment with anti-inflammatory drugs or paracetamol, in combination with non-pharmacological management, is still recommended for most commonly occurring sport injuries.
Author L. SteynSource: SA Pharmaceutical Journal 83, pp 27 –28 (2016)More Less
A blocked, "stuffy" nose is not considered to be a serious condition. However, it has a considerable negative impact on the quality of life of both the parent and child. Infants with blocked noses struggle to breathe while feeding, and young children are unable to blow their noses properly to ease their discomfort. Infants and children with a blocked nose have difficulty sleeping at night too. Parents often seek help on how to clear their child's nose. The focus of this article is how to ease the discomfort of a blocked nose in a child until the condition resolves.
Cost comparison between repackaging bulk oral solid medicines at provincial pharmaceutical depots and purchasing manufacturer-prepared patient-ready packs available on the national contracts in South Africa : pharmaco-economicsSource: SA Pharmaceutical Journal 83, pp 30 –38 (2016)More Less
Background: Patient-ready packs (PRPs) are convenient medicine package sizes to be dispensed to patients. In South Africa, some manufacturer-prepared PRPs are available for procurement by provincial medicine depots on National Contracts. However, when PRPs are not available, bulk medicines must be repackaged into PRPs at the repackaging units of provincial pharmaceutical depots. This research was aimed at determining the less costly method of obtaining PRPs for primary healthcare (PHC) facilities in South Africa.
Method: Site visits to the repackaging units of four depots were conducted to evaluate the repackaging processes and determine all associated costs. These costs were then reduced to represent cost per unit PRP for each medicine line being repackaged. These were then compared with the cost of purchasing manufacturer-prepared equivalent PRPs available on National Contracts.
Results: Overall, four depots were repackaging 96 PRP lines meant for primary healthcare (PHC) facilities. Of these, only 61 (63.5%; n= 96) were available on National Contracts in equivalent pack sizes. The cost of packaging 35 (57.4%; n= 61) of the PRPs by the depots was less than the cost of equivalent pack sizes available on National Contracts. Only 35 (36.5%; n= 96) lines were targeted at the required PRP lines not available on National Contracts.
Conclusion: There is no statistically significant difference between the cost of Manufacturer-prepared PRPs available on National Contracts and equivalent pack sizes made through repackaging at provincial pharmaceutical depots in South Africa.
Author Joggie HattinghSource: SA Pharmaceutical Journal 83 (2016)More Less
There is a perception that SAAHIP is mostly about conferences and for some people it might well be true! Nobody will dispute that Conference is the highlight of the SAAHIP calendar, though. Yet, if we look at what was presented at SAAHIP Conference 2016, by members, on work done in their daily work environment, I feel so proud. As a profession we share our experiences and successes without holding back. We are also willing to present the findings of investigations with warts and all, so that other colleagues can learn from our successes and mistakes. It is very uncomfortable to have the shortcomings of your systems and practises exposed before an audience, yet it is quite enlightening to others, when you reveal how the shortcomings were addressed! The alternative would be to hide all shortcomings and to pretend that there are none, (and don't we all do it at times?) yet the results can be more humiliating when the cracks appear and the dam wall finally breaks.
Author Sandy Van VuurenSource: SA Pharmaceutical Journal 83, pp 43 –44 (2016)More Less
Sandy is the 2015 winner of the Johnson and Johnson Teacher of The Year award. I never thought I would be the academic reiterating the words "Back in my day.....", but yes, I have reached that age. Academic teaching has changed dramatically in the last 16 years that I have been lecturing. I clearly remember my first exposure to the "other side"where I no longer was a student, but suddenly a pharmacy staff member. I started my first day as a technician, all wide eyed, young, energetic and keen to learn. Lorraine Osman (yes, our Madam Editor) held me captive and I have never had a dull moment since. Thirty-two years on and I'm still here, maybe not as young or wide eyed, but certainly ready to match the youth with new challenges.
Source: SA Pharmaceutical Journal 83 (2016)More Less
Source: SA Pharmaceutical Journal 83, pp 49 –50 (2016)More Less
Myoclonic astatic epilepsy is currently treated with valproic acid as the first line treatment of choice. However, this is based on expert opinion due to the paucity of good evidence1. Described here is the case of a 7-year-old boy with myoclonic astatic epilepsy, whose seizures could not be controlled on valproic acid monotherapy, and who rapidly improved with ethosuximide as add-on therapy.
Author Susan BuekesSource: SA Pharmaceutical Journal 83, pp 51 –52 (2016)More Less
I had not made a telephone call to the South African Pharmacy Council (SAPC) for several years, but recently I did so and encountered the vaunted call centre. I listened to a series of messages for nearly five minutes before I was told that due to the high volume of calls I should please wait for the next available call centre agent, and that I was number thirty in line. I promptly hung up. What incensed me about that extraordinary lengthy greeting was that my time was being wasted listening to the Council's various messages and in particular the one about its 2nd Pharmacy Conference, and this on a line used by members of the public as well. I was locked into this monologue which included thanking the Council's Diamond sponsor, Aspen Pharmacare for making the 2016 Conference and the Pioneer awards possible.